Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL) Meeting Abstract
| Authors: | Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; Lue, J. K.; Goldberg, A. D.; Stephens, D. M.; Duffy, V.; Panton, G.; Tyznar, D.; Dorsey, C.; Soni, D.; Hutzler, C.; Nogan, L.; Allen, A.; Nyima, T.; Nguyen, T. Q.; Shah, M.; Cook, T. R.; Abillar-Wright, J.; Brutus, J.; Laudati, C.; Kikani, B.; Coombs, C. C.; Silvestrone, M. R.; Jensen, C. E.; Fakhri, B.; Thompson, M. C. |
| Abstract Title: | Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL) |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 1011 |
| Language: | English |
| ACCESSION: | WOS:001412773700004 |
| DOI: | 10.1182/blood-2024-203807 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
